Global Personalized Tumor Vaccines 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI07252548

Publication Date:

July 2, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Personalized Tumor Vaccines market size is predicted to grow from US$ 155 million in 2025 to US$ 229 million in 2031; it is expected to grow at a CAGR of 6.7% from 2025 to 2031.
Personalized tumor vaccines are a type of customized immunotherapy based on a patient's individual tumor-specific antigens, designed to activate the patient's own immune system to accurately identify and attack tumor cells. Through genome sequencing and bioinformatics analysis, scientists are able to identify unique mutations (i.e., neoantigens) in tumor cells and design and synthesize vaccines targeting these neoantigens.
United States market for Personalized Tumor Vaccines is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Personalized Tumor Vaccines is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Personalized Tumor Vaccines is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Personalized Tumor Vaccines players cover Geneos Therapeutics, BioNTech, Siemens, Moderna, Merck, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淧ersonalized Tumor Vaccines Industry Forecast鈥� looks at past sales and reviews total world Personalized Tumor Vaccines sales in 2024, providing a comprehensive analysis by region and market sector of projected Personalized Tumor Vaccines sales for 2025 through 2031. With Personalized Tumor Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Personalized Tumor Vaccines industry.
This Insight Report provides a comprehensive analysis of the global Personalized Tumor Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Personalized Tumor Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Personalized Tumor Vaccines market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Personalized Tumor Vaccines and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Personalized Tumor Vaccines.
This report presents a comprehensive overview, market shares, and growth opportunities of Personalized Tumor Vaccines market by product type, application, key players and key regions and countries.
Segmentation by Type:
DNA-based
RNA-based
Segmentation by Application:
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Geneos Therapeutics
BioNTech
Siemens
Moderna
Merck
Everest Medicines

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Personalized Tumor Vaccines 麻豆原创 Size (2020-2031)
2.1.2 Personalized Tumor Vaccines 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Personalized Tumor Vaccines by Country/Region (2020, 2024 & 2031)
2.2 Personalized Tumor Vaccines Segment by Type
2.2.1 DNA-based
2.2.2 RNA-based
2.3 Personalized Tumor Vaccines 麻豆原创 Size by Type
2.3.1 Personalized Tumor Vaccines 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Personalized Tumor Vaccines 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Personalized Tumor Vaccines Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Personalized Tumor Vaccines 麻豆原创 Size by Application
2.5.1 Personalized Tumor Vaccines 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Personalized Tumor Vaccines 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Personalized Tumor Vaccines 麻豆原创 Size by Player
3.1 Personalized Tumor Vaccines 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Personalized Tumor Vaccines Revenue by Player (2020-2025)
3.1.2 Global Personalized Tumor Vaccines Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Personalized Tumor Vaccines Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Personalized Tumor Vaccines by Region
4.1 Personalized Tumor Vaccines 麻豆原创 Size by Region (2020-2025)
4.2 Global Personalized Tumor Vaccines Annual Revenue by Country/Region (2020-2025)
4.3 Americas Personalized Tumor Vaccines 麻豆原创 Size Growth (2020-2025)
4.4 APAC Personalized Tumor Vaccines 麻豆原创 Size Growth (2020-2025)
4.5 Europe Personalized Tumor Vaccines 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Personalized Tumor Vaccines 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Personalized Tumor Vaccines 麻豆原创 Size by Country (2020-2025)
5.2 Americas Personalized Tumor Vaccines 麻豆原创 Size by Type (2020-2025)
5.3 Americas Personalized Tumor Vaccines 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Personalized Tumor Vaccines 麻豆原创 Size by Region (2020-2025)
6.2 APAC Personalized Tumor Vaccines 麻豆原创 Size by Type (2020-2025)
6.3 APAC Personalized Tumor Vaccines 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Personalized Tumor Vaccines 麻豆原创 Size by Country (2020-2025)
7.2 Europe Personalized Tumor Vaccines 麻豆原创 Size by Type (2020-2025)
7.3 Europe Personalized Tumor Vaccines 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Personalized Tumor Vaccines by Region (2020-2025)
8.2 Middle East & Africa Personalized Tumor Vaccines 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Personalized Tumor Vaccines 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Personalized Tumor Vaccines 麻豆原创 Forecast
10.1 Global Personalized Tumor Vaccines Forecast by Region (2026-2031)
10.1.1 Global Personalized Tumor Vaccines Forecast by Region (2026-2031)
10.1.2 Americas Personalized Tumor Vaccines Forecast
10.1.3 APAC Personalized Tumor Vaccines Forecast
10.1.4 Europe Personalized Tumor Vaccines Forecast
10.1.5 Middle East & Africa Personalized Tumor Vaccines Forecast
10.2 Americas Personalized Tumor Vaccines Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Personalized Tumor Vaccines Forecast
10.2.2 Canada 麻豆原创 Personalized Tumor Vaccines Forecast
10.2.3 Mexico 麻豆原创 Personalized Tumor Vaccines Forecast
10.2.4 Brazil 麻豆原创 Personalized Tumor Vaccines Forecast
10.3 APAC Personalized Tumor Vaccines Forecast by Region (2026-2031)
10.3.1 China Personalized Tumor Vaccines 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Personalized Tumor Vaccines Forecast
10.3.3 Korea 麻豆原创 Personalized Tumor Vaccines Forecast
10.3.4 Southeast Asia 麻豆原创 Personalized Tumor Vaccines Forecast
10.3.5 India 麻豆原创 Personalized Tumor Vaccines Forecast
10.3.6 Australia 麻豆原创 Personalized Tumor Vaccines Forecast
10.4 Europe Personalized Tumor Vaccines Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Personalized Tumor Vaccines Forecast
10.4.2 France 麻豆原创 Personalized Tumor Vaccines Forecast
10.4.3 UK 麻豆原创 Personalized Tumor Vaccines Forecast
10.4.4 Italy 麻豆原创 Personalized Tumor Vaccines Forecast
10.4.5 Russia 麻豆原创 Personalized Tumor Vaccines Forecast
10.5 Middle East & Africa Personalized Tumor Vaccines Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Personalized Tumor Vaccines Forecast
10.5.2 South Africa 麻豆原创 Personalized Tumor Vaccines Forecast
10.5.3 Israel 麻豆原创 Personalized Tumor Vaccines Forecast
10.5.4 Turkey 麻豆原创 Personalized Tumor Vaccines Forecast
10.6 Global Personalized Tumor Vaccines Forecast by Type (2026-2031)
10.7 Global Personalized Tumor Vaccines Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Personalized Tumor Vaccines Forecast
11 Key Players Analysis
11.1 Geneos Therapeutics
11.1.1 Geneos Therapeutics Company Information
11.1.2 Geneos Therapeutics Personalized Tumor Vaccines Product Offered
11.1.3 Geneos Therapeutics Personalized Tumor Vaccines Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Geneos Therapeutics Main Business Overview
11.1.5 Geneos Therapeutics Latest Developments
11.2 BioNTech
11.2.1 BioNTech Company Information
11.2.2 BioNTech Personalized Tumor Vaccines Product Offered
11.2.3 BioNTech Personalized Tumor Vaccines Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 BioNTech Main Business Overview
11.2.5 BioNTech Latest Developments
11.3 Siemens
11.3.1 Siemens Company Information
11.3.2 Siemens Personalized Tumor Vaccines Product Offered
11.3.3 Siemens Personalized Tumor Vaccines Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Siemens Main Business Overview
11.3.5 Siemens Latest Developments
11.4 Moderna
11.4.1 Moderna Company Information
11.4.2 Moderna Personalized Tumor Vaccines Product Offered
11.4.3 Moderna Personalized Tumor Vaccines Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Moderna Main Business Overview
11.4.5 Moderna Latest Developments
11.5 Merck
11.5.1 Merck Company Information
11.5.2 Merck Personalized Tumor Vaccines Product Offered
11.5.3 Merck Personalized Tumor Vaccines Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Merck Main Business Overview
11.5.5 Merck Latest Developments
11.6 Everest Medicines
11.6.1 Everest Medicines Company Information
11.6.2 Everest Medicines Personalized Tumor Vaccines Product Offered
11.6.3 Everest Medicines Personalized Tumor Vaccines Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Everest Medicines Main Business Overview
11.6.5 Everest Medicines Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.